search
Back to results

Study of Anti-reflux Medication as a Potential Treatment for Glue Ear in Children

Primary Purpose

Otitis Media With Effusion

Status
Completed
Phase
Phase 4
Locations
Canada
Study Type
Interventional
Intervention
Lansoprazole
Placebo
Sponsored by
Hamilton Health Sciences Corporation
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Otitis Media With Effusion

Eligibility Criteria

1 Year - 17 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Children between the ages of 1 and 17 years referred to the McMaster Otolaryngology Clinic.
  • Presence of bilateral OME for at least 3 months based on:

    • Clinical history: patient may present with decrease in hearing, aural fullness and/or ear pressure, balance problems, ear tugging/rubbing, they typically do not have otalgia or fever.
    • Pneumatic otoscopy: observations suggestive of OME include presence of a dull tympanic membrane with presence of non purulent effusion (serous or mucoid), presence of a level of effusion, decrease or non motility of the tympanic membrane, retraction of the tympanic membrane.
    • Tympanometry: type B or type C tympanogram with normal air volume of the external auditory canal.
    • Pure tone audiometry: conductive hearing loss that typically varies from slight to moderate.

Exclusion Criteria:

  • Presence of acute otitis media as determined by history and physical examination:

    • History of rapid acute onset of significant otalgia, decrease in hearing, fever, irritability.
    • Pneumatic otoscopy revealing purulent effusion, yellowness and/or redness with hypervascularity of the tympanic membrane, bulging of tympanic membrane with decrease of normal landmarks.
  • Presence of craniofacial abnormalities
  • Previous middle ear surgery (excluding myringotomy and tube)
  • Allergic reactions to lansoprazole, and any other adverse drug interactions to lansoprazole.

Sites / Locations

  • Mcmaster University Medical Centre 3V1 Clinic

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Lansoprazole

Placebo

Arm Description

Outcomes

Primary Outcome Measures

Collect the required data for sample size calculation
The purpose of this pilot study is to collect required data for a sample size calculation for a larger clinical trial and to determine recruitment rates.

Secondary Outcome Measures

Resolution of Otitis Media with Effusion
The secondary objectives are to compare the duration of OME between the placebo and treatment groups, and to compare the duration and degree of hearing loss at initial presentation and at three months. Other outcomes include degree of hearing improvement, complications of OME (i.e. recurrent OME, acute otitis media, surgery), frequency and severity of GERD symptoms, side effects of Lansoprazole use, and presence of pepsin in middle ear effusions collected from patients who received surgical treatment.

Full Information

First Posted
March 4, 2010
Last Updated
April 12, 2015
Sponsor
Hamilton Health Sciences Corporation
Collaborators
McMaster University
search

1. Study Identification

Unique Protocol Identification Number
NCT01082029
Brief Title
Study of Anti-reflux Medication as a Potential Treatment for Glue Ear in Children
Official Title
Role of Empiric Anti-reflux Therapy in Pediatric Otitis Media With Effusion - a Pilot Study
Study Type
Interventional

2. Study Status

Record Verification Date
April 2015
Overall Recruitment Status
Completed
Study Start Date
March 2010 (undefined)
Primary Completion Date
June 2014 (Actual)
Study Completion Date
June 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Hamilton Health Sciences Corporation
Collaborators
McMaster University

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The accumulation of fluid behind the ear drum without any acute inflammation is known as otitis media with effusion (OME). It is the most common cause of acquired hearing loss during childhood. Long-term complications of OME include linguistic, developmental, and social development delays due to hearing loss. The cause of OME is not known; however, low grade infection of the middle ear, poor function of the eustachian tube between the ear and the throat, and adenoid hypertrophy have all been suggested as possible etiologies. Recent detection of the stomach enzyme pepsin in middle ear fluid has led some to propose that OME is related to the reflux of stomach contents into the ear, via the eustachian tube. The purpose of the investigators study is to determine whether anti-reflux medication may have a positive impact by clearing the accumulation of fluid in the middle ear with the aim of preventing or reducing hearing loss in children diagnosed with OME. Empiric anti-reflux therapy with proton pump inhibitor (PPI) medication is safe, proven and cost-effective. It is used widely as a diagnostic and treatment strategy in the presence of the signs and symptoms of gastroesophageal reflux disease (GERD). The signs and symptoms of GERD include heartburn, recurrent vomiting or regurgitation, acid taste in mouth, throat irritation, voice problems, heartburn, difficult or painful swallowing, asthma and recurrent pneumonia. This pilot study will be a double-blinded, randomized, placebo-controlled trial that will compare resolution rates for OME in children treated with lansoprazole or placebo for three months. At the end of the study, those patients who have persistent middle ear effusions will be brought to the operating room and have the fluid aspirated and sent for analysis for pepsin.
Detailed Description
Otitis media with effusion (OME) is a condition characterized by the accumulation of non-purulent fluid in the middle ear space, in the absence of acute inflammation. OME is diagnosed 2.2 million times annually (U.S. Department of Health & Human Services, 2000). It is a condition in which more then 50% of children will experience in their first year of life (National Institutes of Health, 1993). Although many episodes resolve spontaneously, 30% to 40% persist, and 5% to 10% of episodes last 1 year or longer (Yoshinaga-Itano, 1995). It is particularly more common among children between the ages of one and three years and in seasons where the prevalence of upper respiratory tract infections is high; with an incidence of 10% to 30%. It occurs frequently even up to the age of seven, with a prevalence of 3% to 8%(Fiellau et al, 1997; Fiellau et al, 1983; Lous et al, 1981; Teele et al, 1989). OME is the most common cause of acquired hearing loss in childhood. Long-term hearing complications from OME are associated with linguistic, developmental, and social consequences; especially if the OME is bilateral and of long duration (Fiellau et al, 1983; Golz et al, 1998; Grace et al, 1990; Lous et al, 1995). The etiology of OME is uncertain; however, low-grade infection, poor eustachian tube function, formation of biofilms, and adenoidal infection or hypertrophy have all been suggested as possible etiologies (Faden et al, 1998; Hall-Stoodley et al, 2006). Recently, there has been good scientific evidence to suggest that OME is a supraesophageal manifestation of gastroesophageal reflux disease (GERD), and more specifically laryngo-pharyngeal reflux (LPR). Tasker et al (2002) investigated the potential role of gastric reflux in the development of OME in children who underwent myringotomy. Of 65 tested effusion samples, 59 (91%) effusions gave a positive result. The concentrations of pepsin/pepsinogen were roughly estimated to be about 1000 times higher than those found in the serum obtained from a number of controls. They speculated that pepsin found in middle ear effusion (MEE) was most probably due to micro-aspiration of gastric contents passing through the eustachian tube (ET) and reaching the middle ear. Lieu et al (2005) performed a pilot study where they replicated the finding of pepsin/pepsinogen in 17 of 36 (77%) middle ear fluid aspirates, obtained from 22 children who underwent tympanostomy tube placement for chronic or recurrent otitis media (OM). Based on our literature review, we believe there is sufficient scientific evidence to support the empiric treatment of suspected GERD and LPR in patients with OME. Empiric anti-reflux therapy is a safe, proven, cost-effective diagnostic and treatment strategy used widely in the presence of other signs and symptoms of suspected GERD. This pilot study will be a double-blinded, randomized control trial. It will compare hearing outcomes for children with OME being treated with lansoprazole versus placebo for three months. We believe there is sufficient evidence to support the use of this strategy in patients with suspected GERD and LPR who present with OME.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Otitis Media With Effusion

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
65 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Lansoprazole
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Lansoprazole
Other Intervention Name(s)
Prevacid
Intervention Description
The dosage of Lansoprazole will be administered based on guidelines set out by the prescription drug information outlined in the official Lansoprazole package insert and will remain the same for each patient during the 3 month period and is as follows: a) 1 to 11 years of age, weight less then or equal to 30 kg, 15 mg orally once daily. b) 1 to 11 years of age, weight greater then 30 kg, 30 mg orally once daily. c) 12 years of age and older, 15 mg orally once daily. The doses of Lansoprazole will be prepared in liquid form by the Inpatient Pharmacy at Hamilton Health Sciences.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Lactose powder in 8.4% Sodium Bicarbonate (Liquid placebo)
Primary Outcome Measure Information:
Title
Collect the required data for sample size calculation
Description
The purpose of this pilot study is to collect required data for a sample size calculation for a larger clinical trial and to determine recruitment rates.
Time Frame
Following the recruitment of 100 patients (~1 year)
Secondary Outcome Measure Information:
Title
Resolution of Otitis Media with Effusion
Description
The secondary objectives are to compare the duration of OME between the placebo and treatment groups, and to compare the duration and degree of hearing loss at initial presentation and at three months. Other outcomes include degree of hearing improvement, complications of OME (i.e. recurrent OME, acute otitis media, surgery), frequency and severity of GERD symptoms, side effects of Lansoprazole use, and presence of pepsin in middle ear effusions collected from patients who received surgical treatment.
Time Frame
At presentation and at 1 month, 2months and 3 months post initiation of treatment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Year
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Children between the ages of 1 and 17 years referred to the McMaster Otolaryngology Clinic. Presence of bilateral OME for at least 3 months based on: Clinical history: patient may present with decrease in hearing, aural fullness and/or ear pressure, balance problems, ear tugging/rubbing, they typically do not have otalgia or fever. Pneumatic otoscopy: observations suggestive of OME include presence of a dull tympanic membrane with presence of non purulent effusion (serous or mucoid), presence of a level of effusion, decrease or non motility of the tympanic membrane, retraction of the tympanic membrane. Tympanometry: type B or type C tympanogram with normal air volume of the external auditory canal. Pure tone audiometry: conductive hearing loss that typically varies from slight to moderate. Exclusion Criteria: Presence of acute otitis media as determined by history and physical examination: History of rapid acute onset of significant otalgia, decrease in hearing, fever, irritability. Pneumatic otoscopy revealing purulent effusion, yellowness and/or redness with hypervascularity of the tympanic membrane, bulging of tympanic membrane with decrease of normal landmarks. Presence of craniofacial abnormalities Previous middle ear surgery (excluding myringotomy and tube) Allergic reactions to lansoprazole, and any other adverse drug interactions to lansoprazole.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dr. Diane Reid, MD FRCSC
Organizational Affiliation
McMaster University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Dr. Gavin Rukholm, MD
Organizational Affiliation
McMaster University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mcmaster University Medical Centre 3V1 Clinic
City
Hamilton
State/Province
Ontario
ZIP/Postal Code
L8N 3Z5
Country
Canada

12. IPD Sharing Statement

Citations:
PubMed Identifier
4819098
Citation
Bluestone CD, Beery QC, Andrus WS. Mechanics of the Eustachian tube as it influences susceptibility to and persistence of middle ear effusions in children. Ann Otol Rhinol Laryngol. 1974 Mar-Apr;83:Suppl 11:27-34. doi: 10.1177/0003489474083s1103. No abstract available.
Results Reference
background
PubMed Identifier
15667483
Citation
Charbel S, Khandwala F, Vaezi MF. The role of esophageal pH monitoring in symptomatic patients on PPI therapy. Am J Gastroenterol. 2005 Feb;100(2):283-9. doi: 10.1111/j.1572-0241.2005.41210.x.
Results Reference
background
PubMed Identifier
17585281
Citation
Crapko M, Kerschner JE, Syring M, Johnston N. Role of extra-esophageal reflux in chronic otitis media with effusion. Laryngoscope. 2007 Aug;117(8):1419-23. doi: 10.1097/MLG.0b013e318064f177.
Results Reference
background
PubMed Identifier
16056096
Citation
Deal L, Gold BD, Gremse DA, Winter HS, Peters SB, Fraga PD, Mack ME, Gaylord SM, Tolia V, Fitzgerald JF. Age-specific questionnaires distinguish GERD symptom frequency and severity in infants and young children: development and initial validation. J Pediatr Gastroenterol Nutr. 2005 Aug;41(2):178-85. doi: 10.1097/01.mpg.0000172885.77795.0f.
Results Reference
background
PubMed Identifier
10527293
Citation
Fass R, Ofman JJ, Gralnek IM, Johnson C, Camargo E, Sampliner RE, Fennerty MB. Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease. Arch Intern Med. 1999 Oct 11;159(18):2161-8. doi: 10.1001/archinte.159.18.2161.
Results Reference
background
PubMed Identifier
609889
Citation
Fiellau-Nikolajsen M, Lous J, Vang Pedersen S, Schousboe HH. Tympanometry in three-year-old children. I. A regional prevalence study on the distribution of tympanometric results in a non-selected population of 3-year-old children. Scand Audiol. 1977;6(4):199-204. doi: 10.3109/01050397709043121.
Results Reference
background
PubMed Identifier
464883
Citation
Fiellau-Nikolajsen M, Lous J. Prospective tympanometry in 3-year-old children. A study of the spontaneous course of tympanometry types in a nonselected population. Arch Otolaryngol. 1979 Aug;105(8):461-6. doi: 10.1001/archotol.1979.00790200023005.
Results Reference
background
PubMed Identifier
6314732
Citation
Fiellau-Nikolajsen M. Tympanometry and secretory otitis media. Observations on diagnosis, epidemiology, treatment, and prevention in prospective cohort studies of three-year-old children. Acta Otolaryngol Suppl. 1983;394:1-73. No abstract available.
Results Reference
background
PubMed Identifier
10685741
Citation
Gerson LB, Robbins AS, Garber A, Hornberger J, Triadafilopoulos G. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease. Am J Gastroenterol. 2000 Feb;95(2):395-407. doi: 10.1111/j.1572-0241.2000.01759.x.
Results Reference
background
PubMed Identifier
9852553
Citation
Golz A, Netzer A, Angel-Yeger B, Westerman ST, Gilbert LM, Joachims HZ. Effects of middle ear effusion on the vestibular system in children. Otolaryngol Head Neck Surg. 1998 Dec;119(6):695-9. doi: 10.1016/S0194-5998(98)70039-7.
Results Reference
background
PubMed Identifier
2230572
Citation
Grace AR, Pfleiderer AG. Dysequilibrium and otitis media with effusion: what is the association? J Laryngol Otol. 1990 Sep;104(9):682-4. doi: 10.1017/s0022215100113611.
Results Reference
background
PubMed Identifier
11642425
Citation
Heavner SB, Hardy SM, White DR, Prazma J, Pillsbury HC 3rd. Transient inflammation and dysfunction of the eustachian tube secondary to multiple exposures of simulated gastroesophageal refluxant. Ann Otol Rhinol Laryngol. 2001 Oct;110(10):928-34. doi: 10.1177/000348940111001007.
Results Reference
background
PubMed Identifier
12512644
Citation
Hicks DM, Ours TM, Abelson TI, Vaezi MF, Richter JE. The prevalence of hypopharynx findings associated with gastroesophageal reflux in normal volunteers. J Voice. 2002 Dec;16(4):564-79. doi: 10.1016/s0892-1997(02)00132-7.
Results Reference
background
PubMed Identifier
16484116
Citation
Jonaitis L, Pribuisiene R, Kupcinskas L, Uloza V. Laryngeal examination is superior to endoscopy in the diagnosis of the laryngopharyngeal form of gastroesophageal reflux disease. Scand J Gastroenterol. 2006 Feb;41(2):131-7. doi: 10.1080/00365520600577940.
Results Reference
background
PubMed Identifier
15768814
Citation
Keles B, Ozturk K, Gunel E, Arbag H, Ozer B. Pharyngeal reflux in children with chronic otitis media with effusion. Acta Otolaryngol. 2004 Dec;124(10):1178-81. doi: 10.1080/00016480410017134.
Results Reference
background
PubMed Identifier
16143181
Citation
Lieu JE, Muthappan PG, Uppaluri R. Association of reflux with otitis media in children. Otolaryngol Head Neck Surg. 2005 Sep;133(3):357-61. doi: 10.1016/j.otohns.2005.05.654.
Results Reference
background
PubMed Identifier
6976949
Citation
Lous J, Fiellau-Nikolajsen M. Epidemiology and middle ear effusion and tubal dysfunction. A one-year prospective study comprising monthly tympanometry in 387 non-selected 7-year-old children. Int J Pediatr Otorhinolaryngol. 1981 Dec;3(4):303-17. doi: 10.1016/0165-5876(81)90055-0.
Results Reference
background
PubMed Identifier
7729171
Citation
Lous J. Secretory otitis media in schoolchildren. Is screening for secretory otitis media advisable? Dan Med Bull. 1995 Feb;42(1):71-99. No abstract available.
Results Reference
background
PubMed Identifier
16335860
Citation
Rodriguez-Tellez M. Supra-oesophageal manifestations of gastro-oesophageal reflux disease. Drugs. 2005;65 Suppl 1:67-73. doi: 10.2165/00003495-200565001-00010.
Results Reference
background
PubMed Identifier
11964951
Citation
Rozmanic V, Velepic M, Ahel V, Bonifacic D, Velepic M. Prolonged esophageal pH monitoring in the evaluation of gastroesophageal reflux in children with chronic tubotympanal disorders. J Pediatr Gastroenterol Nutr. 2002 Mar;34(3):278-80. doi: 10.1097/00005176-200203000-00009.
Results Reference
background
PubMed Identifier
12945555
Citation
Shekelle P, Takata G, Chan LS, Mangione-Smith R, Corley PM, Morphew T, Morton S. Diagnosis, natural history, and late effects of otitis media with effusion. Evid Rep Technol Assess (Summ). 2002 Jun;(55):1-5. doi: 10.1037/e439822005-001. No abstract available.
Results Reference
background
PubMed Identifier
12439157
Citation
Tasker A, Dettmar PW, Panetti M, Koufman JA, P Birchall J, Pearson JP. Is gastric reflux a cause of otitis media with effusion in children? Laryngoscope. 2002 Nov;112(11):1930-4. doi: 10.1097/00005537-200211000-00004.
Results Reference
background
PubMed Identifier
2732519
Citation
Teele DW, Klein JO, Rosner B. Epidemiology of otitis media during the first seven years of life in children in greater Boston: a prospective, cohort study. J Infect Dis. 1989 Jul;160(1):83-94. doi: 10.1093/infdis/160.1.83.
Results Reference
background
PubMed Identifier
12160291
Citation
White DR, Heavner SB, Hardy SM, Prazma J. Gastroesophageal reflux and eustachian tube dysfunction in an animal model. Laryngoscope. 2002 Jun;112(6):955-61. doi: 10.1097/00005537-200206000-00004.
Results Reference
background
PubMed Identifier
16327839
Citation
Vaezi MF. Therapy Insight: gastroesophageal reflux disease and laryngopharyngeal reflux. Nat Clin Pract Gastroenterol Hepatol. 2005 Dec;2(12):595-603. doi: 10.1038/ncpgasthep0358.
Results Reference
background
PubMed Identifier
15513526
Citation
Velepic MM, Velepic MS, Starcevic R, Manestar D, Rozmanic V. Gastroesophageal reflux and sequelae of chronic tubotympanal disorders in children. Acta Otolaryngol. 2004 Oct;124(8):914-7. doi: 10.1080/00016480410022499.
Results Reference
background
PubMed Identifier
19128594
Citation
Al-Saab F, Manoukian JJ, Al-Sabah B, Almot S, Nguyen LH, Tewfik TL, Daniel SJ, Schloss MD, Hamid QA. Linking laryngopharyngeal reflux to otitis media with effusion: pepsinogen study of adenoid tissue and middle ear fluid. J Otolaryngol Head Neck Surg. 2008 Aug;37(4):565-71.
Results Reference
background

Learn more about this trial

Study of Anti-reflux Medication as a Potential Treatment for Glue Ear in Children

We'll reach out to this number within 24 hrs